Enzymes

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

Retrieved on: 
星期五, 五月 14, 2021
Branches of biology, Biology, Life sciences, Enzymes, Metabolism, Gene therapy, Genetic engineering, Fast track, 21-Hydroxylase, Aldosterone

The FDA\xe2\x80\x99s Fast Track designation reinforces the urgency to address the unmet needs of patients with CAH as quickly and safely as possible.

Key Points: 
  • The FDA\xe2\x80\x99s Fast Track designation reinforces the urgency to address the unmet needs of patients with CAH as quickly and safely as possible.
  • We are grateful to have received Fast Track along with other key designations granted by the FDA and the EMA,\xe2\x80\x9d said Eric David, M.D., J.D., CEO at BridgeBio Gene Therapy, which is focused on developing gene therapy treatment options for patients in need.
  • The disease is caused by deleterious mutations in the gene encoding an enzyme called 21-hydroxylase, leading to lack of endogenous cortisol and aldosterone production.
  • The presentation covered three key Investigational New Drug (IND)-enabling studies that informed the anticipated upcoming clinical trial for BBP-631.

Global Acetyl-Coa Carboxylase Inhibitors Pipeline Insight Report 2021 Featuring Emerging Drugs Such as Firsocostat: Gilead Sciences & Clesacostat: Pfizer - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 13, 2021
Health, Pharmaceutical, Enzymes, Metabolism, Acetyl-CoA carboxylase, Acetyl-CoA, (acetyl-CoA carboxylase) kinase, Metabolic pathways, (acetyl-CoA carboxylase)-phosphatase

b'The "Acetyl-Coa Carboxylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points: 
  • b'The "Acetyl-Coa Carboxylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThis segment of the Acetyl-CoA carboxylase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • 3+ key companies which are developing the Acetyl-CoA carboxylase inhibitors.
  • The companies which have their Acetyl-CoA carboxylase inhibitors drug candidates in the most advanced stage, i.e.

Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors

Retrieved on: 
星期三, 五月 12, 2021
Physical sciences, Antioxidants, Radiobiology, Oxidoreductases, Enzymes, Superoxide dismutase mimetics, Chemistry, Natural sciences, Radiation therapy, Dismutase, Mucositis, Radiation

The synergy between the mimetic and radiotherapy increased with larger daily doses (\xe2\x80\x9cfractions\xe2\x80\x9d) of radiation.

Key Points: 
  • The synergy between the mimetic and radiotherapy increased with larger daily doses (\xe2\x80\x9cfractions\xe2\x80\x9d) of radiation.
  • Moreover, in the range of fraction sizes typical of SBRT, the combination ablated many of the tumors.
  • In addition, as previously published, the authors report that by removing the superoxide, the dismutase mimetics protected normal cells from radiation toxicity.
  • Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).

Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time

Retrieved on: 
星期一, 五月 10, 2021
Enzymes, IDH1, IDH2, Isocitrate dehydrogenase, Brain tumor, Rare diseases, Oncology

The evaluation of several gene mutations is now becoming standard of care for diagnosis, prognostic stratification, and differentially tailored treatment strategies1.

Key Points: 
  • The evaluation of several gene mutations is now becoming standard of care for diagnosis, prognostic stratification, and differentially tailored treatment strategies1.
  • IDH2 mutations can be associated with IDH1 mutation.5\nKIT: This mutation expression is found in approximately 80% of AML cases.
  • Patients with a KIT mutation have a poor prognosis and clinical outcome, therefore potentially requiring more aggressive treatment.
  • These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed.

DGAP-News: BRAIN Biotech AG: Genome Editing Tool Developed by BRAIN

Retrieved on: 
星期四, 五月 6, 2021
Branches of biology, Biology, Genetic engineering, Genome editing, Life sciences, Immune system, Biotechnology, Enzymes, CRISPR, Cas9, CRISPR gene editing, Protospacer adjacent motif

The CRISPR-CAS system has provided a genetic tool with speed as well as simplicity that was previously unavailable to science.\nBRAIN has developed a novel CRISPR Cas tool using metagenomics sequencing and protein engineering to isolate a Non-Cas9 genome editing nuclease.

Key Points: 
  • The CRISPR-CAS system has provided a genetic tool with speed as well as simplicity that was previously unavailable to science.\nBRAIN has developed a novel CRISPR Cas tool using metagenomics sequencing and protein engineering to isolate a Non-Cas9 genome editing nuclease.
  • Michael Krohn, Head R&D at BRAIN Biotech AG emphasizes: "The market for genome editing tools based on the CRISPR Cas mechanism is just emerging and offers significant growth opportunities.
  • "\nLukas Linnig, CFO BRAIN Biotech AG, says: " We are very pleased by what we have already achieved and currently explore the best business model to further accelerate the development of this exciting genome editing tool.
  • Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group.

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

Retrieved on: 
星期四, 五月 6, 2021
Entospletinib, Indazoles, Morpholines, Tyrosine-protein kinase SYK, Enzymes, Acute myeloid leukemia, Tyrosine kinase, NPM1, Protein kinase inhibitors

A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.

Key Points: 
  • A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • For more information, visit www.kronosbio.com or follow the company on LinkedIn .\n'

ADP National Employment Report: Private Sector Employment Increased by 742,000 Jobs in April

Retrieved on: 
星期三, 五月 5, 2021
Enzymes, ADP, Payroll, ADP National Employment Report, NAD(P)(+)—protein-arginine ADP-ribosyltransferase, NAD(+)—diphthamide ADP-ribosyltransferase

"\nThe matched sample used to develop the ADP National Employment Report was derived from ADP payroll data, which represents 460,000 U.S. clients employing nearly 26 million workers in the U.S.

Key Points: 
  • "\nThe matched sample used to develop the ADP National Employment Report was derived from ADP payroll data, which represents 460,000 U.S. clients employing nearly 26 million workers in the U.S.
  • The March total of jobs added was revised from 517,000 to 565,000.\nTo obtain additional information about the ADP National Employment Report, including additional charts, supporting data and the schedule of future release dates, or to subscribe to the monthly email alerts and RSS feeds, please visit www.adpemploymentreport.com .\nThe May 2021 ADP National Employment Report will be released at 8:15 a.m.
  • ET on June 3, 2021.\nThe ADP National Employment ReportTM is a monthly measure of the change in total U.S. nonfarm private employment derived from actual, anonymous payroll data of client companies served by ADP, a leading provider of human capital management solutions.
  • Learn more at ADP.com\nADP, the ADP logo, and Always Designing for People, ADP National Employment Report, ADP Small Business Report, ADP National Franchise Report, and ADP Research Institute are registered trademarks of ADP, Inc. All other marks are the property of their respective owners.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/adp-national-employment-report-p...\n'

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
星期三, 五月 5, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, Neuraminidase, BioCryst Pharmaceuticals, XC2, Viral neuraminidase

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

ChromaDex and Ro Partner for New Product Development

Retrieved on: 
星期二, 五月 4, 2021
Seniors, Fitness & Nutrition, Biotechnology, Other Health, Health, Consumer, General Health, Other Science, Science, Enzymes, Nicotinamide riboside, ChromaDex, B vitamins, Nicotinamide adenine dinucleotide, NAD, Nicotinamide, Elysium Health

b'ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen\xc2\xae with Ro, a healthcare-technology company.

Key Points: 
  • b'ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen\xc2\xae with Ro, a healthcare-technology company.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), which is protected by ChromaDex\xe2\x80\x99s patent portfolio along with other NAD+ precursors.
  • Since 2017, Ro has facilitated more than six million digital healthcare visits in nearly every county in the United States, including 98% of primary care deserts.

Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors

Retrieved on: 
星期一, 五月 3, 2021
Enzymes, FASN, Fatty acid synthase, Synthase, Grammer

b'SAN MATEO, Calif., May 3, 2021 /PRNewswire/ --Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors.

Key Points: 
  • b'SAN MATEO, Calif., May 3, 2021 /PRNewswire/ --Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors.
  • We look forward to leveraging her extensive experience to help Sagimet grow our business.
  • In her role, Ms. Grammer oversees legal, intellectual property, government affairs and policy, and compliance.
  • She also has significant experience in business and corporate development, and human resources.\n"I am excited to join Sagimet\'s board of directors.